New benzimidazole derivatives containing hydrazone group as anticancer agents: Inhibition of carbonic anhydrase IX and molecular docking studies

Basit Öğe Kaydı
dc.contributor.authorBostanci, Hayrani Eren
dc.contributor.authorYildiz, Mehmet Taha
dc.contributor.authorKapancik, Serkan
dc.contributor.authorInan, Zeynep Deniz Sahin
dc.contributor.authorKilic, Haci Ahmet
dc.contributor.authorGuler, Ozen Ozensoy
dc.contributor.authorCevik, Ulviye Acar
dc.date.accessioned2025-05-04T16:47:37Z
dc.date.available2025-05-04T16:47:37Z
dc.date.issued2025
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractIn this study, we propose identifying potential novel compounds targeting carbonic anhydrase (CA) IX and anticancer activity. To study the impact of these synthesized compounds on CA IX and anticancer activity, we have developed and synthesized novel benzimidazole-hydrazone derivatives (3a-3j). The target compounds' H-1 NMR (nuclear magnetic resonance), C-13 NMR, and high resolution mass spectrometry spectra were used to confirm their chemical structures. L929 (healthy mouse fibroblast cell line) used as control healthy cell line and MCF-7 (breast cancer), C6 (rat glioblastoma), HT-29 (colon cancer), cells were used in cell culture studies. As a result of cell culture studies, it was determined that the newly synthesized compounds 3d and 3j had cytotoxic effects on colon cancer. Again, it was determined that the compound 3d had a more toxic effect than cisplatin on both breast cancer and glioma cells. According to the CA IX activity results, compounds 3d and 3j were found to have the highest activity. Compounds 3d and 3j are essential for having anti-cancer properties and inhibiting the carbonic anhydrase IX enzyme. Molecular docking of these compounds was carried out in the active site of CA IX. Flow cytometry and immunofluorescence microscope analyses also confirmed that these compounds had cytotoxic effects on cancer cells.
dc.description.sponsorshipAnadolu University Medicinal Plant Drug and Scientific Research and Application Center (AUBIBAM)
dc.description.sponsorshipThe authors thank Anadolu University Medicinal Plant Drug and Scientific Research and Application Center (AUBIBAM) for their support and contributions.
dc.identifier.doi10.1002/ardp.202400930
dc.identifier.issn0365-6233
dc.identifier.issn1521-4184
dc.identifier.issue3
dc.identifier.pmid40123434
dc.identifier.scopus2-s2.0-105000730309
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1002/ardp.202400930
dc.identifier.urihttps://hdl.handle.net/20.500.12418/35675
dc.identifier.volume358
dc.identifier.wosWOS:001450123900001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWiley-V C H Verlag Gmbh
dc.relation.ispartofArchiv Der Pharmazie
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250504
dc.subjectbenzimidazole
dc.subjectcarbonic anhydrase IX
dc.subjectflow cytometry
dc.subjectmolecular docking
dc.titleNew benzimidazole derivatives containing hydrazone group as anticancer agents: Inhibition of carbonic anhydrase IX and molecular docking studies
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu